New Guidelines Broaden Eligibility for Cholesterol-Lowering Treatment

New 2026 guidelines for hyperlipidemia treatment significantly expand eligibility for lipid-lowering therapy, now including 54.6% of adults aged 20–79 without established cardiovascular disease. This 13.3 percentage-point increase from 2018 guidelines means more individuals, particularly women and older adults, are now recommended for treatment, potentially impacting public health outcomes.